Piramal Pharma Secures UK Approval for Pediatric Infusion Neoatricon

Piramal Pharma Ltd announced that its subsidiary, Piramal Critical Care (PCC), and Ireland-based BrePco Biopharma Ltd (BPCO) have received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for Neoatricon. This marks a significant milestone as Neoatricon becomes the first paediatric-strength dopamine hydrochloride infusion designed for neonates, infants, and children with hypotension.

Addressing a Critical Gap in Paediatric Care

Neoatricon, developed by BrePco Biopharma, is a ready-to-use, sterile dopamine hydrochloride infusion solution available in two strengths: 1.5mg/mL (30 mL vial) for neonates and smaller infants, and 4.5mg/mL (50 mL vial) for infants, children above 10 kg, and adolescents requiring cardiovascular support.

Before this approval, there was no authorised dopamine hydrochloride formulation specifically indicated for paediatric use, with off-label administration being common. Neoatricon ensures precise dosing, reducing the risk of medication errors and minimising preparation time in neonatal and paediatric intensive care units (NICU & PICU). This advancement facilitates faster intervention, particularly in emergency settings.

Piramal Critical Care’s Role in Commercialisation

Piramal Critical Care has secured commercialisation rights for Neoatricon across the EU, UK, and Norway and will oversee its distribution. The approval signifies PCC’s expansion into paediatric critical care, reinforcing its position as a global leader in anaesthesia, pain management, intrathecal therapy, and critical care medicine.

The development of Neoatricon was supported by the European Commission’s 7th Framework Programme, highlighting the commitment to improving paediatric healthcare solutions.

Piramal Pharma Share Performance 

As of March 21, 2025, at 11:55 AM, Piramal Pharma’s share price is trading at ₹223.95 per share, reflecting a surge of 1.20% from the previous day’s closing price. Over the past month, the stock has surged by 7.13%.

Conclusion

The approval of Neoatricon introduces a dedicated paediatric-strength dopamine hydrochloride formulation, filling a crucial gap in critical care medicine. This milestone strengthens Piramal Critical Care’s footprint in paediatric healthcare, ensuring safer and more effective treatment for young patients in need of cardiovascular support.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.